Interesting, if there do so it_老虎社区_美港股上老虎

2021-05-14

Interesting, if there do so it will change a lot of things

Samsung BioLogics says no decision yet on producing Moderna's COVID-19 shot

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":198255710,"tweetId":"198255710","gmtCreate":1620964454630,"gmtModify":1634194905023,"author":{"id":3549802203532457,"idStr":"3549802203532457","authorId":3549802203532457,"authorIdStr":"3549802203532457","name":"KasonT","avatar":"https://static.tigerbbs.com/27ab5f369fba0bf66b2ffb94ea148a0f","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Interesting, if there do so it will change a lot of things</p></body></html>","htmlText":"<html><head></head><body><p>Interesting, if there do so it will change a lot of things</p></body></html>","text":"Interesting, if there do so it will change a lot of things","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/198255710","repostId":2135685676,"repostType":4,"repost":{"id":"2135685676","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1620954458,"share":"https://www.laohu8.com/m/news/2135685676?lang=&edition=full","pubTime":"2021-05-14 09:07","market":"us","language":"en","title":"Samsung BioLogics says no decision yet on producing Moderna's COVID-19 shot","url":"https://stock-news.laohu8.com/highlight/detail?id=2135685676","media":"Reuters","summary":"SEOUL, May 14 (Reuters) - Samsung BioLogics Co Ltd said on Friday that no decision has been made yet","content":"<p>SEOUL, May 14 (Reuters) - Samsung BioLogics Co Ltd&nbsp;said on Friday that no decision has been made yet on producing Moderna Inc's    COVID-19 vaccine in South Korea after a local newspaper reported the two companies had agreed on a contract manufacturing deal.</p><p>The Chosun Ilbo reported that the biotech arm of Samsung Group has agreed to produce the Moderna vaccine in its plant in Songdo, part of which will be used for domestic vaccination, citing unnamed government and pharmaceutical industry sources.</p><p>Samsung BioLogics said in a filing to the stock exchange that it could confirm the report as no decision has been finalised. The decision will be made within a <a href=\"https://laohu8.com/S/AONE\">one</a>-month time frame, a company official told Reuters by phone.</p><p>The statement follows a denial by Samsung and Pfizer Inc</p><p>earlier this week of another media report that the two companies were working together to produce a COVID-19 vaccine developed by the U.S. firm and its German partner BioNTech.</p><p>The Moderna shot has yet to be approved in South Korea, but the second of three expert panels recommended approval for emergency use of the vaccine on Thursday, based on its safety and efficacy in Phase 3 late-stage trials in the United States.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Samsung BioLogics says no decision yet on producing Moderna's COVID-19 shot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSamsung BioLogics says no decision yet on producing Moderna's COVID-19 shot\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-05-14 09:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SEOUL, May 14 (Reuters) - Samsung BioLogics Co Ltd&nbsp;said on Friday that no decision has been made yet on producing Moderna Inc's    COVID-19 vaccine in South Korea after a local newspaper reported the two companies had agreed on a contract manufacturing deal.</p><p>The Chosun Ilbo reported that the biotech arm of Samsung Group has agreed to produce the Moderna vaccine in its plant in Songdo, part of which will be used for domestic vaccination, citing unnamed government and pharmaceutical industry sources.</p><p>Samsung BioLogics said in a filing to the stock exchange that it could confirm the report as no decision has been finalised. The decision will be made within a <a href=\"https://laohu8.com/S/AONE\">one</a>-month time frame, a company official told Reuters by phone.</p><p>The statement follows a denial by Samsung and Pfizer Inc</p><p>earlier this week of another media report that the two companies were working together to produce a COVID-19 vaccine developed by the U.S. firm and its German partner BioNTech.</p><p>The Moderna shot has yet to be approved in South Korea, but the second of three expert panels recommended approval for emergency use of the vaccine on Thursday, based on its safety and efficacy in Phase 3 late-stage trials in the United States.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2135685676","content_text":"SEOUL, May 14 (Reuters) - Samsung BioLogics Co Ltd said on Friday that no decision has been made yet on producing Moderna Inc's    COVID-19 vaccine in South Korea after a local newspaper reported the two companies had agreed on a contract manufacturing deal.The Chosun Ilbo reported that the biotech arm of Samsung Group has agreed to produce the Moderna vaccine in its plant in Songdo, part of which will be used for domestic vaccination, citing unnamed government and pharmaceutical industry sources.Samsung BioLogics said in a filing to the stock exchange that it could confirm the report as no decision has been finalised. The decision will be made within a one-month time frame, a company official told Reuters by phone.The statement follows a denial by Samsung and Pfizer Incearlier this week of another media report that the two companies were working together to produce a COVID-19 vaccine developed by the U.S. firm and its German partner BioNTech.The Moderna shot has yet to be approved in South Korea, but the second of three expert panels recommended approval for emergency use of the vaccine on Thursday, based on its safety and efficacy in Phase 3 late-stage trials in the United States.","news_type":1},"isVote":1,"tweetType":1,"viewCount":222,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":47,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/198255710"}